SCHEMBL3243143

SCHEMBL3243143

Cc1ccc2cncc(O)c2n1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 1/20 0.57
RAB9A P51151 2/20 0.50
CCR1 P32246 1/20 0.50
CCR5 P51681 1/20 0.50
KMT2A Q03164 3/20 0.46
OPRK1 P41145 1/20 0.46
KDM4E B2RXH2 3/20 0.39
ALDH1A1 P00352 3/20 0.39
MAPT P10636 2/20 0.38
CTSB P07858 1/20 0.38
CTSH P09668 1/20 0.38
PARP1 P09874 1/20 0.37
HPGD P15428 2/20 0.36
HSD17B10 Q99714 2/20 0.36
USP2 O75604 1/20 0.36
BDKRB2 P30411 1/20 0.36
CYP1A2 P05177 2/20 0.34
MEN1 O00255 2/20 0.34
NPC1 O15118 1/20 0.33
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13348672 0.79 ALDH1A1 (0.42) METAP2RAB9AKMT2AKDM4EALDH1A1
SCHEMBL12086500 0.78 CCR1 (0.54) METAP2RAB9ACCR1CCR5KMT2A
SCHEMBL3275027 0.75 METAP2 (0.57) METAP2RAB9ACCR1CCR5KMT2A
SCHEMBL4579898 0.75 CCR1 (0.50) METAP2RAB9ACCR1CCR5KMT2A
SCHEMBL12330452 0.75 CCR1 (0.50) METAP2RAB9ACCR1CCR5KMT2A
SCHEMBL27192221 0.75 CCR1 (0.50) METAP2RAB9ACCR1CCR5KMT2A
SCHEMBL31509691 0.75 CCR1 (0.50) METAP2RAB9ACCR1CCR5KMT2A
8-Hydroxy Quinaldine SCHEMBL29483489 0.72 METAP2 (1.00) METAP2RAB9ACCR1CCR5KMT2A
8-Hydroxy Quinaldine SCHEMBL297247 0.72 METAP2 (1.00) METAP2RAB9ACCR1CCR5KMT2A
SCHEMBL20247361 0.72 CCR1 (0.46) METAP2RAB9ACCR1CCR5KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2210892-A2 Neurologically-active compounds Prana Biotechnology Limited (AU) 2010-07-28 EP disclosed
US-20100160346-A1 NEUROLOGICALLY ACTIVE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2010-06-24 US disclosed
US-20100160346-A1 NEUROLOGICALLY ACTIVE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2010-06-24 US disclosed
US-7692011-B2 8-hydroxy and 8-mercapto quinazolinones PRANA BIOTECHNOLOGY LIMITED (AU) 2010-04-06 US disclosed
US-7692011-B2 8-hydroxy and 8-mercapto quinazolinones PRANA BIOTECHNOLOGY LIMITED (AU) 2010-04-06 US disclosed
EP-1558585-A4 NEUROLOGICALLY-ACTIVE COMPOUNDS PRANA BIOTECHNOLOGY LTD (AU) 2008-07-02 EP disclosed
US-20060167000-A1 Neurologically-active compounds PRANA BIOTECHNOLOGY LIMITED (AU) 2006-07-27 US disclosed
EP-1558585-A1 NEUROLOGICALLY-ACTIVE COMPOUNDS Prana Biotechnology Ltd (AU) 2005-08-03 EP disclosed
WO-2004031161-A1 NEUROLOGICALLY-ACTIVE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2004-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167000-A1 Neurologically-active compounds ACHE, PSEN1, PSEN2 METAP2 2008/4885RAB9A 574/4885CCR1 4583/4885
US-20100160346-A1 NEUROLOGICALLY ACTIVE COMPOUNDS ACHE, PSEN1, PSEN2 METAP2 1931/4885RAB9A 684/4885CCR1 4660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.